Top Markets
#1 Trillions Trillions +4,371.27%
#2 Ozapay Ozapay +38.46%
#3 UnifAI Network UnifAI Network +23.35%
#4 Aria.AI Aria.AI +22.13%
#5 Zano Zano +17.76%
#6 Osaka Protocol Osaka Protocol +14.37%
#7 StakeStone StakeStone +14.34%
#8 Vestra DAO Vestra DAO +12.12%
#9 River Pts River Pts +10.84%
#10 Janction Janction +10.23%
Coin of the day
Trillions Trillions
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Classifica tra le azioni #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Prezzo delle azioni
$0.28545656
Capitalizzazione di mercato
$4.50M
Variazione (1 giorno)
5.97%
Variazione (1 anno)
0.00%
Paese
FR
Scambia Acticor Biotech SAS (ALACT)

Categoria

Healthcare
Rapporto P/B per Acticor Biotech SAS (ALACT)
Rapporto P/B al March 2026 TTM: -0.57
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Acticor Biotech SAS, il rapporto P/B attuale (TTM) è -0.57. Alla fine del 2022, era pari a -33.19.
Storico del rapporto P/B per Acticor Biotech SAS da 2010 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 -1,096.18%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 -1,224.18%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 -532.31%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 -868.45%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5504 -549.09%
AU